Bio-Rad Laboratories (BIO) Operating Leases (2019 - 2026)

Bio-Rad Laboratories (BIO) has reported Operating Leases for 8 consecutive years, with $166.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Leases fell 18.32% year-over-year to $166.7 million in Q2 2026; TTM through Jun 2026 was $166.7 million, a 18.32% decrease from a year earlier, with the FY2025 full-year figure at $181.8 million, up 5.03% from the prior year.
• Operating Leases was $166.7 million for Q2 2026 at Bio-Rad Laboratories, down from $174.8 million in the prior quarter.
• Over five years, Operating Leases peaked at $206.5 million in Q1 2022 and troughed at $166.7 million in Q2 2026.
• A 5-year average of $188.3 million and a median of $188.3 million in 2022 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases advanced 13.79% in 2023 and dropped 18.32% in 2026, its largest moves.
• Over 5 years, Operating Leases stood at $189.9 million in 2022, then rose by 8.43% to $205.9 million in 2023, then fell by 15.93% to $173.1 million in 2024, then gained by 5.03% to $181.8 million in 2025, then fell by 8.31% to $166.7 million in 2026.
• The last three Operating Leases figures came in at $166.7 million (Q2 2026), $174.8 million (Q1 2026), and $181.8 million (Q4 2025), per Business Quant data.